Skip to main content

16.05.2024 | Original Article

FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis

verfasst von: Peter George Maliha, Masatoshi Hotta, Andrea Farolfi, Tristan Grogan, Rejah Alano, Andrea Limon, Ethan Lam, Giuseppe Carlucci, Shadfar Bahri, Ali Salavati, Matthias Benz, Daniel Silverman, Pawan Gupta, Andrew Quon, Martin Allen-Auerbach, Johannes Czernin, Jeremie Calais

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Fibroblast activation protein (FAP)-inhibitor (FAPI)-PET tracers allow imaging of the FAP-expressing cancer associated fibroblasts (CAF) and also the normal activated fibroblasts (NAF) involved in inflammation/fibrosis that may be present after invasive medical interventions. We evaluated [68Ga]Ga-FAPI-46 uptake patterns post-medical/invasive non-systemic interventions.

Methods

This single-center retrospective analysis was conducted in 79 consecutive patients who underwent [68Ga]Ga-FAPI-46 PET/CT. Investigators reviewed prior patient medical/invasive interventions (surgery, endoscopy, biopsy, radiotherapy, foreign body placement (FBP) defined as implanted medical/surgical material present at time of scan) and characterized the anatomically corresponding FAPI uptake intensity both visually (positive if above surrounding background) and quantitatively (SUVmax). Interventions with missing data/images or confounders of [68Ga]Ga-FAPI-46 uptake (partial volume effect, other cause of increased uptake) were excluded. Available correlative FDG, DOTATATE and PSMA PET/CTs were analyzed when available.

Results

163 medical/invasive interventions (mostly surgeries (49%), endoscopies (18%) and non-surgical biopsies (10%)) in 60 subjects were included for analysis. 43/163 (26%) involved FBP. FAPI uptake occurred in 24/163 (15%) of interventions (average SUVmax 3.2 (mild), range 1.5–5.1). The median time-interval post-intervention to FAPI-PET was 47.5 months and was shorter when FAPI uptake was present (median 9.5 months) than when absent (median 60.1 months; p = 0.001). Cut-off time beyond which no FAPI uptake would be present post-intervention without FBP was 8.2 months, with a sensitivity, specificity, positive predictive value and negative predictive value of 82, 90, 99 and 31% respectively. No optimal cutoff point could be determined when considering interventions with FBP. No significant difference was detected between frequency of [68Ga]Ga-FAPI-46 and [18F]FDG uptake in intervention sites. Compared to [68Ga]Ga-PSMA-11, [68Ga]Ga-FAPI-46 revealed more frequent and intense post-interventional tracer uptake.

Conclusion

[68Ga]Ga-FAPI-46 uptake from medical/invasive interventions without FBP appears to be time dependent, nearly always absent beyond 8 months post-intervention, but frequently present for years with FBP.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
16.
Zurück zum Zitat Babensee JE. 2.2.2 - Inflammation, Wound Healing, the Foreign-Body Response, and Alternative Tissue Responses, in Biomaterials Science (Fourth Edition), Wagner WR, et al. Editors. Academic Press; 2020. p. 737–746. Babensee JE. 2.2.2 - Inflammation, Wound Healing, the Foreign-Body Response, and Alternative Tissue Responses, in Biomaterials Science (Fourth Edition), Wagner WR, et al. Editors. Academic Press; 2020. p. 737–746.
20.
Zurück zum Zitat Guevara YM, et al. FAP PET/CT imaging in radiation induced pulmonary fibrosis. J Nucl Med. 2023;64(supplement 1):P1536–P1536. Guevara YM, et al. FAP PET/CT imaging in radiation induced pulmonary fibrosis. J Nucl Med. 2023;64(supplement 1):P1536–P1536.
Metadaten
Titel
FAPI PET uptake patterns after invasive medical interventions: a single center retrospective analysis
verfasst von
Peter George Maliha
Masatoshi Hotta
Andrea Farolfi
Tristan Grogan
Rejah Alano
Andrea Limon
Ethan Lam
Giuseppe Carlucci
Shadfar Bahri
Ali Salavati
Matthias Benz
Daniel Silverman
Pawan Gupta
Andrew Quon
Martin Allen-Auerbach
Johannes Czernin
Jeremie Calais
Publikationsdatum
16.05.2024
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-024-06733-7